Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05038904
Other study ID # IRB00223615
Secondary ID
Status Completed
Phase Phase 2
First received
Last updated
Start date December 16, 2021
Est. completion date December 31, 2022

Study information

Verified date September 2023
Source Johns Hopkins University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Food allergy is a potentially life-threatening condition, and its prevalence continues to increase despite public health efforts. There are currently no known therapies that can reliably prevent food-induced anaphylaxis. This is an open-label study designed to determine the ability acalabrutinib to prevent signs and symptoms of anaphylaxis during an oral food challenge in food-allergic adults.


Description:

Approximately 15 million people (including 8% of children) in the US have a food allergy and are at risk for life-threatening systemic reactions to foods. There is an unmet need for treatments capable of preventing such reactions. This is a phase II, single-center, open label trial involving the use of acalabrutinib (brand name Calquence®) to prevent food-induced anaphylaxis in adults with food allergy. Acalabrutinib is FDA-approved to treat certain medical conditions, but it is not approved to treat allergies. Adult participants with a physician-diagnosed food allergy to peanut and/or tree nuts will be enrolled. These participants will undergo an oral food challenge to peanut or a tree nut under close physician supervision to determine participants' baseline reactivity. After a rest period, the participants will take 4 oral doses of acalabrutinib 100 mg, and then repeat the oral food challenge to see if acalabrutinib will reduce participants' reactivity to peanut or tree nuts.


Recruitment information / eligibility

Status Completed
Enrollment 10
Est. completion date December 31, 2022
Est. primary completion date December 8, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - History of immunoglobulin E (IgE)-mediated food allergy to peanut or tree nut - Positive skin prick test to the trigger food (either peanut or tree nut) - Objective clinical reaction to the food allergen during baseline oral food challenge - Women of child bearing potential must agree to two forms of highly effective contraception (hormonal, device, or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation, and for 7 days following completion of acalabrutinib therapy. - Ability to understand and the willingness to sign a written informed consent - Ability to clearly understand and speak English at an 8th grade reading level Exclusion Criteria: - Participants who have been on immunomodulatory therapies or oral corticosteroids within 1 month prior to enrollment - Participants with symptoms consistent with food reactions other than type 1 hypersensitivity - History of allergic reaction to acalabrutinib - History of idiopathic urticaria, dermatographism, idiopathic or unexplained anaphylaxis, or anaphylaxis (to foods or otherwise) resulting in intubation, prolonged hypotension, or neurological sequelae- History of cardiovascular disease - History of a bleeding disorder, or those currently taking blood thinners - History of stroke - History of gastrointestinal ulcer - History of cancer (other than skin cancer) - Positive HIV status or history of other immunodeficiency - Active or latent Hepatitis B or C infection based on laboratory testing - Currently pregnant or nursing - Current use of proton pump inhibitors (Note: participants currently receiving proton pump inhibitors who switch to H2-receptor antagonists or other antacids are eligible for enrollment to this study). - Active significant infection - Major surgical procedure within 28 days of enrollment - Uncontrolled autoimmune hemolytic anemia or idiopathic thrombocytopenic purpura - Difficulty swallowing oral medication, or significant gastrointestinal disease that would limit absorption of oral medication - Concurrent participation in another therapeutic clinical trial

Study Design


Intervention

Drug:
Acalabrutinib
100 mg oral capsule

Locations

Country Name City State
United States Johns Hopkins Bayview Medical Center Baltimore Maryland

Sponsors (2)

Lead Sponsor Collaborator
Johns Hopkins University AstraZeneca

Country where clinical trial is conducted

United States, 

References & Publications (1)

Suresh RV, Dunnam C, Vaidya D, Wood RA, Bochner BS, MacGlashan DW Jr, Dispenza MC. A phase II study of Bruton's tyrosine kinase inhibition for the prevention of anaphylaxis. J Clin Invest. 2023 Aug 15;133(16):e172335. doi: 10.1172/JCI172335. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Highest Dose of Peanut That is Tolerated During Oral Food Challenge The highest dose of peanut protein (in mg) tolerated during oral food challenge before and after acalabrutinib treatment was determined by assessing clinical symptoms and physcial exam findings in each organ system during the challenge. Symptoms were given a numeric score based on the American Academy of Allergy, Asthma, and Immunology/European Academy of Allergy and Clinical Immunology PRACTALL consensus system to grade symptom severity and the likelihood of their representing a true objective clinical reaction to peanut. Baseline and Day 2 of treatment
Secondary Area Under the Curve Severity of Clinical Reaction to Peanut The severity of participants' cliinical reaction during oral food challenge before and after acalabrutinib treatment was determined using the American Academy of Allergy, Asthma, and Immunology/European Academy of Allergy and Clinical Immunology PRACTALL consensus system to grade objective clinical findings on physical exam on a scale of 0 (absent) to 3 (severe) in 9 different organ system categories. Total symptom scores for each food dose ranged from a minimum if 0 (no symptoms) to 27 (severe objective symptoms in all organ systems), and the area under the curve for all scores during the food challenge were calculated for each participant. Baseline and Day 2 of treatment
Secondary Skin Prick Test Size to Peanut The skin prick test to peanut extract wheal area (in square mm) was measured at baseline and after treatment. Baseline and Day 2 of treatment
Secondary Basophil Activation Testing The percent of peripheral blood basophils activated by stimulation ex vivo with peanut extract was assessed by CD63 surface expression. Baseline and Day 2 of treatment
See also
  Status Clinical Trial Phase
Withdrawn NCT03089476 - Evaluating Skin Barrier Dysfunction in Infants at High Risk of Atopy N/A
Recruiting NCT05839405 - Food Allergy in the Brain
Completed NCT02552537 - iFAAM: The Impact of Proton-pump Inhibitors (Antacids) on Threshold Dose Distributions Phase 4
Completed NCT01634737 - Crustacean Allergy and Dust Mites Sensitization N/A
Completed NCT05072665 - Fast Allergy Sensitivity Test N/A
Active, not recruiting NCT04887441 - Allergology: Information, Data and Knowledge Organization
Recruiting NCT03265262 - The Basophil Activation Test as a Diagnostic Tool in Pediatric Food Allergy N/A
Completed NCT04186949 - Early Origins of Allergy and Asthma
Completed NCT02490007 - Pertussis Immunisation and Food Allergy
Recruiting NCT03151252 - Improvement of Foodallergy Diagnostic in Gastrointestinal Tract N/A
Completed NCT02159833 - Intranasal Diagnostics in Food Allergy: a Feasibility Study N/A
Completed NCT02354729 - Encouraging Allergic Young Adults to Carry Epinephrine N/A
Completed NCT02377284 - Prevention and Management of Food Allergies N/A
Completed NCT02640560 - One-year Survey of Anaphylaxis in Outpatient Children Allergic to Peanuts, Walnuts/Hazelnuts, Shellfish N/A
Enrolling by invitation NCT06097572 - Improved Diagnostics in Food Allergy Study N/A
Recruiting NCT04606615 - Skin Barrier Abnormalities and Oxidative Stress Response
Recruiting NCT05785299 - Clinical Versus Home Introduction of Milk in Children With Non-IgE-mediated Cow's Milk Allergy N/A
Not yet recruiting NCT06112873 - Quality of Life in Food Allergy: Validation of Three Mini-questionnaires
Completed NCT03337802 - Effect of Mediterranean Diet During Pregnancy on the Onset of Overweight and Obesity in the Offspring N/A
Not yet recruiting NCT06085118 - Observatory on Cow's Milk Protein Allergy